1 Overactive Bladder Drug Market Overview 1.1 Product Overview and Scope of Overactive Bladder Drug 1.2 Overactive Bladder Drug Segment by Type 1.2.1 Global Overactive Bladder Drug Sales Growth Rate Comparison by Type (2022-2028) 1.2.2 Anticholinergics 1.2.3 Solifenacin 1.2.4 Oxybutynin 1.2.5 Darifenacin 1.2.6 Fesoterodine 1.2.7 Tolterodine 1.2.8 Trospium 1.2.9 Others 1.3 Overactive Bladder Drug Segment by Application 1.3.1 Global Overactive Bladder Drug Sales Comparison by Application: (2022-2028) 1.3.2 Idiopathic Bladder Overactivity 1.3.3 Neurogenic Bladder Overactivity 1.4 Global Overactive Bladder Drug Market Size Estimates and Forecasts 1.4.1 Global Overactive Bladder Drug Revenue 2017-2028 1.4.2 Global Overactive Bladder Drug Sales 2017-2028 1.4.3 Overactive Bladder Drug Market Size by Region: 2017 Versus 2021 Versus 2028 2 Overactive Bladder Drug Market Competition by Manufacturers 2.1 Global Overactive Bladder Drug Sales Market Share by Manufacturers (2017-2022) 2.2 Global Overactive Bladder Drug Revenue Market Share by Manufacturers (2017-2022) 2.3 Global Overactive Bladder Drug Average Price by Manufacturers (2017-2022) 2.4 Manufacturers Overactive Bladder Drug Manufacturing Sites, Area Served, Product Type 2.5 Overactive Bladder Drug Market Competitive Situation and Trends 2.5.1 Overactive Bladder Drug Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Overactive Bladder Drug Players Market Share by Revenue 2.5.3 Global Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Overactive Bladder Drug Retrospective Market Scenario by Region 3.1 Global Overactive Bladder Drug Retrospective Market Scenario in Sales by Region: 2017-2022 3.2 Global Overactive Bladder Drug Retrospective Market Scenario in Revenue by Region: 2017-2022 3.3 North America Overactive Bladder Drug Market Facts & Figures by Country 3.3.1 North America Overactive Bladder Drug Sales by Country 3.3.2 North America Overactive Bladder Drug Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Overactive Bladder Drug Market Facts & Figures by Country 3.4.1 Europe Overactive Bladder Drug Sales by Country 3.4.2 Europe Overactive Bladder Drug Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Overactive Bladder Drug Market Facts & Figures by Region 3.5.1 Asia Pacific Overactive Bladder Drug Sales by Region 3.5.2 Asia Pacific Overactive Bladder Drug Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Overactive Bladder Drug Market Facts & Figures by Country 3.6.1 Latin America Overactive Bladder Drug Sales by Country 3.6.2 Latin America Overactive Bladder Drug Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Overactive Bladder Drug Market Facts & Figures by Country 3.7.1 Middle East and Africa Overactive Bladder Drug Sales by Country 3.7.2 Middle East and Africa Overactive Bladder Drug Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 UAE 4 Global Overactive Bladder Drug Historic Market Analysis by Type 4.1 Global Overactive Bladder Drug Sales Market Share by Type (2017-2022) 4.2 Global Overactive Bladder Drug Revenue Market Share by Type (2017-2022) 4.3 Global Overactive Bladder Drug Price by Type (2017-2022) 5 Global Overactive Bladder Drug Historic Market Analysis by Application 5.1 Global Overactive Bladder Drug Sales Market Share by Application (2017-2022) 5.2 Global Overactive Bladder Drug Revenue Market Share by Application (2017-2022) 5.3 Global Overactive Bladder Drug Price by Application (2017-2022) 6 Key Companies Profiled 6.1 Astellas Pharma, Inc. (Japan) 6.1.1 Astellas Pharma, Inc. (Japan) Corporation Information 6.1.2 Astellas Pharma, Inc. (Japan) Description and Business Overview 6.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.1.4 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Portfolio 6.1.5 Astellas Pharma, Inc. (Japan) Recent Developments/Updates 6.2 Pfizer, Inc. (US) 6.2.1 Pfizer, Inc. (US) Corporation Information 6.2.2 Pfizer, Inc. (US) Description and Business Overview 6.2.3 Pfizer, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.2.4 Pfizer, Inc. (US) Overactive Bladder Drug Product Portfolio 6.2.5 Pfizer, Inc. (US) Recent Developments/Updates 6.3 Teva Pharmaceutical Industries Limited (Israel) 6.3.1 Teva Pharmaceutical Industries Limited (Israel) Corporation Information 6.3.2 Teva Pharmaceutical Industries Limited (Israel) Description and Business Overview 6.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.3.4 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Portfolio 6.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Developments/Updates 6.4 Allergan, Plc (Ireland) 6.4.1 Allergan, Plc (Ireland) Corporation Information 6.4.2 Allergan, Plc (Ireland) Description and Business Overview 6.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.4.4 Allergan, Plc (Ireland) Overactive Bladder Drug Product Portfolio 6.4.5 Allergan, Plc (Ireland) Recent Developments/Updates 6.5 Medtronic plc (Ireland) 6.5.1 Medtronic plc (Ireland) Corporation Information 6.5.2 Medtronic plc (Ireland) Description and Business Overview 6.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.5.4 Medtronic plc (Ireland) Overactive Bladder Drug Product Portfolio 6.5.5 Medtronic plc (Ireland) Recent Developments/Updates 6.6 Mylan N.V. (US) 6.6.1 Mylan N.V. (US) Corporation Information 6.6.2 Mylan N.V. (US) Description and Business Overview 6.6.3 Mylan N.V. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.6.4 Mylan N.V. (US) Overactive Bladder Drug Product Portfolio 6.6.5 Mylan N.V. (US) Recent Developments/Updates 6.7 Endo International plc (Ireland) 6.6.1 Endo International plc (Ireland) Corporation Information 6.6.2 Endo International plc (Ireland) Description and Business Overview 6.6.3 Endo International plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.4.4 Endo International plc (Ireland) Overactive Bladder Drug Product Portfolio 6.7.5 Endo International plc (Ireland) Recent Developments/Updates 6.8 Hisamitsu Pharmaceutical Co., Inc. (Japan) 6.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Corporation Information 6.8.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Description and Business Overview 6.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Portfolio 6.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments/Updates 6.9 Sanofi (France) 6.9.1 Sanofi (France) Corporation Information 6.9.2 Sanofi (France) Description and Business Overview 6.9.3 Sanofi (France) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.9.4 Sanofi (France) Overactive Bladder Drug Product Portfolio 6.9.5 Sanofi (France) Recent Developments/Updates 6.10 Apotex, Inc. (Canada) 6.10.1 Apotex, Inc. (Canada) Corporation Information 6.10.2 Apotex, Inc. (Canada) Description and Business Overview 6.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.10.4 Apotex, Inc. (Canada) Overactive Bladder Drug Product Portfolio 6.10.5 Apotex, Inc. (Canada) Recent Developments/Updates 6.11 Cogentix Medical, Inc. (US) 6.11.1 Cogentix Medical, Inc. (US) Corporation Information 6.11.2 Cogentix Medical, Inc. (US) Overactive Bladder Drug Description and Business Overview 6.11.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.11.4 Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Portfolio 6.11.5 Cogentix Medical, Inc. (US) Recent Developments/Updates 6.12 Aurobindo Pharma Limited (India) 6.12.1 Aurobindo Pharma Limited (India) Corporation Information 6.12.2 Aurobindo Pharma Limited (India) Overactive Bladder Drug Description and Business Overview 6.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022) 6.12.4 Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Portfolio 6.12.5 Aurobindo Pharma Limited (India) Recent Developments/Updates 7 Overactive Bladder Drug Manufacturing Cost Analysis 7.1 Overactive Bladder Drug Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Overactive Bladder Drug 7.4 Overactive Bladder Drug Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Overactive Bladder Drug Distributors List 8.3 Overactive Bladder Drug Customers 9 Overactive Bladder Drug Market Dynamics 9.1 Overactive Bladder Drug Industry Trends 9.2 Overactive Bladder Drug Market Drivers 9.3 Overactive Bladder Drug Market Challenges 9.4 Overactive Bladder Drug Market Restraints 10 Global Market Forecast 10.1 Overactive Bladder Drug Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Overactive Bladder Drug by Type (2023-2028) 10.1.2 Global Forecasted Revenue of Overactive Bladder Drug by Type (2023-2028) 10.2 Overactive Bladder Drug Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Overactive Bladder Drug by Application (2023-2028) 10.2.2 Global Forecasted Revenue of Overactive Bladder Drug by Application (2023-2028) 10.3 Overactive Bladder Drug Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Overactive Bladder Drug by Region (2023-2028) 10.3.2 Global Forecasted Revenue of Overactive Bladder Drug by Region (2023-2028) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Overactive Bladder Drug Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million) Table 2. Global Overactive Bladder Drug Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million) Table 3. Global Overactive Bladder Drug Market Size by Region (US$ Million) (2017 VS 2021 VS 2028) Table 4. Global Overactive Bladder Drug Market Competitive Situation by Manufacturers in 2021 Table 5. Global Overactive Bladder Drug Sales (K Units) of Key Manufacturers (2017-2022) Table 6. Global Overactive Bladder Drug Sales Market Share by Manufacturers (2017-2022) Table 7. Global Overactive Bladder Drug Revenue (US$ Million) by Manufacturers (2017-2022) Table 8. Global Overactive Bladder Drug Revenue Share by Manufacturers (2017-2022) Table 9. Global Market Overactive Bladder Drug Average Price (USD/Unit) of Key Manufacturers (2017-2022) Table 10. Manufacturers Overactive Bladder Drug Manufacturing Sites and Area Served Table 11. Manufacturers Overactive Bladder Drug Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Overactive Bladder Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overactive Bladder Drug as of 2021) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Overactive Bladder Drug Sales by Region (2017-2022) & (K Units) Table 16. Global Overactive Bladder Drug Sales Market Share by Region (2017-2022) Table 17. Global Overactive Bladder Drug Revenue by Region (2017-2022) & (US$ Million) Table 18. Global Overactive Bladder Drug Revenue Market Share by Region (2017-2022) Table 19. North America Overactive Bladder Drug Sales by Country (2017-2022) & (K Units) Table 20. North America Overactive Bladder Drug Sales Market Share by Country (2017-2022) Table 21. North America Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million) Table 22. North America Overactive Bladder Drug Revenue Market Share by Country (2017-2022) Table 23. Europe Overactive Bladder Drug Sales by Country (2017-2022) & (K Units) Table 24. Europe Overactive Bladder Drug Sales Market Share by Country (2017-2022) Table 25. Europe Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million) Table 26. Europe Overactive Bladder Drug Revenue Market Share by Country (2017-2022) Table 27. Asia Pacific Overactive Bladder Drug Sales by Region (2017-2022) & (K Units) Table 28. Asia Pacific Overactive Bladder Drug Sales Market Share by Region (2017-2022) Table 29. Asia Pacific Overactive Bladder Drug Revenue by Region (2017-2022) & (US$ Million) Table 30. Asia Pacific Overactive Bladder Drug Revenue Market Share by Region (2017-2022) Table 31. Latin America Overactive Bladder Drug Sales by Country (2017-2022) & (K Units) Table 32. Latin America Overactive Bladder Drug Sales Market Share by Country (2017-2022) Table 33. Latin America Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million) Table 34. Latin America Overactive Bladder Drug Revenue Market Share by Country (2017-2022) Table 35. Middle East and Africa Overactive Bladder Drug Sales by Country (2017-2022) & (K Units) Table 36. Middle East and Africa Overactive Bladder Drug Sales Market Share by Country (2017-2022) Table 37. Middle East and Africa Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million) Table 38. Middle East and Africa Overactive Bladder Drug Revenue Market Share by Country (2017-2022) Table 39. Global Overactive Bladder Drug Sales by Type (2017-2022) & (K Units) Table 40. Global Overactive Bladder Drug Sales Market Share by Type (2017-2022) Table 41. Global Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million) Table 42. Global Overactive Bladder Drug Revenue Share by Type (2017-2022) Table 43. Global Overactive Bladder Drug Price by Type (2017-2022) & (USD/Unit) Table 44. Global Overactive Bladder Drug Sales (K Units) by Application (2017-2022) Table 45. Global Overactive Bladder Drug Sales Market Share by Application (2017-2022) Table 46. Global Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million) Table 47. Global Overactive Bladder Drug Revenue Share by Application (2017-2022) Table 48. Global Overactive Bladder Drug Price by Application (2017-2022) & (USD/Unit) Table 49. Astellas Pharma, Inc. (Japan) Corporation Information Table 50. Astellas Pharma, Inc. (Japan) Description and Business Overview Table 51. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 52. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Table 53. Astellas Pharma, Inc. (Japan) Recent Developments/Updates Table 54. Pfizer, Inc. (US) Corporation Information Table 55. Pfizer, Inc. (US) Description and Business Overview Table 56. Pfizer, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 57. Pfizer, Inc. (US) Overactive Bladder Drug Product Table 58. Pfizer, Inc. (US) Recent Developments/Updates Table 59. Teva Pharmaceutical Industries Limited (Israel) Corporation Information Table 60. Teva Pharmaceutical Industries Limited (Israel) Description and Business Overview Table 61. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 62. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Table 63. Teva Pharmaceutical Industries Limited (Israel) Recent Developments/Updates Table 64. Allergan, Plc (Ireland) Corporation Information Table 65. Allergan, Plc (Ireland) Description and Business Overview Table 66. Allergan, Plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 67. Allergan, Plc (Ireland) Overactive Bladder Drug Product Table 68. Allergan, Plc (Ireland) Recent Developments/Updates Table 69. Medtronic plc (Ireland) Corporation Information Table 70. Medtronic plc (Ireland) Description and Business Overview Table 71. Medtronic plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 72. Medtronic plc (Ireland) Overactive Bladder Drug Product Table 73. Medtronic plc (Ireland) Recent Developments/Updates Table 74. Mylan N.V. (US) Corporation Information Table 75. Mylan N.V. (US) Description and Business Overview Table 76. Mylan N.V. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 77. Mylan N.V. (US) Overactive Bladder Drug Product Table 78. Mylan N.V. (US) Recent Developments/Updates Table 79. Endo International plc (Ireland) Corporation Information Table 80. Endo International plc (Ireland) Description and Business Overview Table 81. Endo International plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 82. Endo International plc (Ireland) Overactive Bladder Drug Product Table 83. Endo International plc (Ireland) Recent Developments/Updates Table 84. Hisamitsu Pharmaceutical Co., Inc. (Japan) Corporation Information Table 85. Hisamitsu Pharmaceutical Co., Inc. (Japan) Description and Business Overview Table 86. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 87. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Table 88. Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments/Updates Table 89. Sanofi (France) Corporation Information Table 90. Sanofi (France) Description and Business Overview Table 91. Sanofi (France) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 92. Sanofi (France) Overactive Bladder Drug Product Table 93. Sanofi (France) Recent Developments/Updates Table 94. Apotex, Inc. (Canada) Corporation Information Table 95. Apotex, Inc. (Canada) Description and Business Overview Table 96. Apotex, Inc. (Canada) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 97. Apotex, Inc. (Canada) Overactive Bladder Drug Product Table 98. Apotex, Inc. (Canada) Recent Developments/Updates Table 99. Cogentix Medical, Inc. (US) Corporation Information Table 100. Cogentix Medical, Inc. (US) Description and Business Overview Table 101. Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 102. Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Table 103. Cogentix Medical, Inc. (US) Recent Developments/Updates Table 104. Aurobindo Pharma Limited (India) Corporation Information Table 105. Aurobindo Pharma Limited (India) Description and Business Overview Table 106. Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 107. Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Table 108. Aurobindo Pharma Limited (India) Recent Developments/Updates Table 109. Production Base and Market Concentration Rate of Raw Material Table 110. Key Suppliers of Raw Materials Table 111. Overactive Bladder Drug Distributors List Table 112. Overactive Bladder Drug Customers List Table 113. Overactive Bladder Drug Market Trends Table 114. Overactive Bladder Drug Market Drivers Table 115. Overactive Bladder Drug Market Challenges Table 116. Overactive Bladder Drug Market Restraints Table 117. Global Overactive Bladder Drug Sales Forecast by Type (2023-2028) & (K Units) Table 118. Global Overactive Bladder Drug Sales Market Share Forecast by Type (2023-2028) Table 119. Global Overactive Bladder Drug Revenue Forecast by Type (2023-2028) & (US$ Million) Table 120. Global Overactive Bladder Drug Revenue Market Share Forecast by Type (2023-2028) Table 121. Global Overactive Bladder Drug Sales Forecast by Application (2023-2028) & (K Units) Table 122. Global Overactive Bladder Drug Sales Market Share Forecast by Application (2023-2028) Table 123. Global Overactive Bladder Drug Revenue Forecast by Application (2023-2028) & (US$ Million) Table 124. Global Overactive Bladder Drug Revenue Market Share Forecast by Application (2023-2028) Table 125. Global Overactive Bladder Drug Sales Forecast by Region (2023-2028) & (K Units) Table 126. Global Overactive Bladder Drug Sales Market Share Forecast by Region (2023-2028) Table 127. Global Overactive Bladder Drug Revenue Forecast by Region (2023-2028) & (US$ Million) Table 128. Global Overactive Bladder Drug Revenue Market Share Forecast by Region (2023-2028) Table 129. Research Programs/Design for This Report Table 130. Key Data Information from Secondary Sources Table 131. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Overactive Bladder Drug Figure 2. Global Overactive Bladder Drug Market Share by Type in 2021 & 2028 Figure 3. Anticholinergics Product Picture Figure 4. Solifenacin Product Picture Figure 5. Oxybutynin Product Picture Figure 6. Darifenacin Product Picture Figure 7. Fesoterodine Product Picture Figure 8. Tolterodine Product Picture Figure 9. Trospium Product Picture Figure 10. Others Product Picture Figure 11. Global Overactive Bladder Drug Market Share by Application in 2021 & 2028 Figure 12. Idiopathic Bladder Overactivity Figure 13. Neurogenic Bladder Overactivity Figure 14. Global Overactive Bladder Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 15. Global Overactive Bladder Drug Market Size (2017-2028) & (US$ Million) Figure 16. Global Overactive Bladder Drug Sales (2017-2028) & (K Units) Figure 17. Overactive Bladder Drug Sales Share by Manufacturers in 2021 Figure 18. Global Overactive Bladder Drug Revenue Share by Manufacturers in 2021 Figure 19. The Global 5 and 10 Largest Overactive Bladder Drug Players: Market Share by Revenue in 2021 Figure 20. Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 21. Global Overactive Bladder Drug Sales Market Share by Region (2017-2022) Figure 22. Global Overactive Bladder Drug Sales Market Share by Region in 2021 Figure 23. Global Overactive Bladder Drug Revenue Market Share by Region (2017-2022) Figure 24. Global Overactive Bladder Drug Revenue Market Share by Region in 2021 Figure 25. U.S. Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 26. Canada Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 27. Germany Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 28. France Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 29. U.K. Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 30. Italy Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 31. Russia Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 32. China Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 33. Japan Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 34. South Korea Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 35. India Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 36. Australia Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 37. Taiwan Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 38. Indonesia Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 39. Thailand Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 40. Malaysia Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 41. Philippines Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 42. Vietnam Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 43. Mexico Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 44. Brazil Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 45. Argentina Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 46. Turkey Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 47. Saudi Arabia Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 48. UAE Overactive Bladder Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 49. Sales Market Share of Overactive Bladder Drug by Type (2017-2022) Figure 50. Manufacturing Cost Structure of Overactive Bladder Drug Figure 51. Manufacturing Process Analysis of Overactive Bladder Drug Figure 52. Overactive Bladder Drug Industrial Chain Analysis Figure 53. Channels of Distribution Figure 54. Distributors Profiles Figure 55. Bottom-up and Top-down Approaches for This Report Figure 56. Data Triangulation Figure 57. Key Executives Interviewed

Astellas Pharma, Inc. (Japan) Pfizer, Inc. (US) Teva Pharmaceutical Industries Limited (Israel) Allergan, Plc (Ireland) Medtronic plc (Ireland) Mylan N.V. (US) Endo International plc (Ireland) Hisamitsu Pharmaceutical Co., Inc. (Japan) Sanofi (France) Apotex, Inc. (Canada) Cogentix Medical, Inc. (US) Aurobindo Pharma Limited (India)